Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193805-26-001463·BridgeBio Oncology Therapeutics, Inc.
Schedule 13G ownership disclosure
BridgeBio Oncology Therapeutics Inc
Common Stock · CUSIP: 107924102
Event date: 2026-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deerfield Mgmt, L.P.
Shares: 1,569,083.00 · Class: 1.96%
- Deerfield Mgmt V, L.P.
Shares: 1,569,084.00 · Class: 1.96%
- Deerfield Partners, L.P.
Shares: 1,569,083.00 · Class: 1.96%
- Deerfield Private Design Fund V, L.P.
Shares: 1,569,084.00 · Class: 1.96%
- Deerfield Management Company, L.P.
Shares: 3,138,167.00 · Class: 3.91%
- James E. Flynn
Shares: 3,138,167.00 · Class: 3.91%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193805-26-001463
- Form type
- SCHEDULE 13G/A
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Nov 13, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership